Skip to content
Nikang Therapeutics
Nikang Therapeutics
  • About Us
  • Science & Pipeline
  • News
  • Careers
  • Home
  • About us
  • Science & Pipeline
  • News
  • Careers

NiKang Therapeutics® Presents Discovery of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader for Cancer Therapy at SABCS 2025

See the press release on Business Wire

Contact Us

Please use this form to contact the NiKang Therapeutics team for all inquiries.

Nikang Therapeutics

200 Powder Mill Road
Bldg E500
Wilmington, DE 19803

P:

302-415-5127
info@nikangtx.com
www.nikangtx.com

© 2023 NiKang Therapeutics, Inc. All Rights Reserved.

Privacy Policy | Terms & Conditions

Go to Top